Get the Stockscreener App
47.17
1.35%
0.33
Q 32 Bio Inc stock is traded at $47.17, with a volume of 49,881.
It is up +1.35% in the last 24 hours and up +6.08% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
See More
Previous Close:
$46.84
Open:
$46.28
24h Volume:
49,881
Relative Volume:
0.48
Market Cap:
$575.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.53%
1M Performance:
+6.08%
6M Performance:
+85.50%
1Y Performance:
+0.00%
1-Day Range:
$46.07
$48.48
1-Week Range:
$45.00
$49.68
52-Week Range:
$13.59
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Q 32 Bio Inc Stock (QTTB) Latest News
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - Kilgore News Herald
Brokerages Set Q32 Bio Inc. (NASDAQ:QTTB) Target Price at $72.33 - Defense World
Q32 Bio (NASDAQ:QTTB) Shares Down 3.6%Time to Sell? - MarketBeat
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight - India Shorts
Q32 Bio (NASDAQ:QTTB) Stock Price Up 5% – Here’s Why - Defense World
Q32 Bio (NASDAQ:QTTB) Stock Price Up 5%Here's What Happened - MarketBeat
Raymond James Initiates Coverage of Q32 Bio (QTTB) with Strong Buy Recommendation - MSN
Q32 Bio (NASDAQ:QTTB) Research Coverage Started at Raymond James - MarketBeat
Upstream Bio stock rallies 32% following upsized $255M IPO - MSN
Oppenheimer Maintains Bullish Stance on Q32 Bio with Robust Clinical Outlook - Yahoo Finance
Oppenheimer Maintains Bullish Stance on Q32 Bio with Robust Clin - GuruFocus.com
ADX-097, potential AAV therapy, fares well in healthy volunteers - ANCA Vasculitis News
Oppenheimer holds stock target, upbeat on Q32 Bio ahead of data - Investing.com
Oppenheimer holds stock target, upbeat on Q32 Bio ahead of data By Investing.com - Investing.com South Africa
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 - cnhinews.com
Renaissance Technologies LLC Buys 685,151 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
Renaissance Technologies LLC Decreases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Citizens Community Bancorp, Inc. (NASDAQ:CZWI) Shares Sold by Renaissance Technologies LLC - Defense World
Renaissance Technologies LLC Grows Stock Holdings in OptimumBank Holdings, Inc. (NASDAQ:OPHC) - Defense World
Renaissance Technologies LLC Acquires Shares of 66,500 Waldencast plc (NASDAQ:WALD) - Defense World
Renaissance Technologies LLC Takes $265,000 Position in Q32 Bio Inc. (NASDAQ:QTTB) - MarketBeat
Renaissance Technologies LLC Buys Shares of 84,300 Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
private equity firms who own 52% along with institutions invested in Q32 Bio Inc. (NASDAQ:QTTB) saw increase in their holdings value last week - Simply Wall St
Q32 Bio (NASDAQ:QTTB) Shares Up 4.8% – What’s Next? - Defense World
Q32 Bio (NASDAQ:QTTB) Stock Price Up 4.8%What's Next? - MarketBeat
Analysts Set Q32 Bio Inc. (NASDAQ:QTTB) PT at $68.80 - MarketBeat
Q32 Bio Inc. Patent Woes: Navigating the Perilous Waters of Intellectual Property Disputes - TipRanks
Q32 Bio's SWOT analysis: emerging biotech stock targets inflammatory diseases - Investing.com India
Q32 Bio's SWOT analysis: emerging biotech stock targets inflammatory diseases By Investing.com - Investing.com South Africa
Sherwin-Williams (SHW) Set to Announce Quarterly Earnings on Monday - Defense World
Ensign Peak Advisors Inc Purchases 38,750 Shares of Q32 Bio Inc. (NASDAQ:QTTB) - MarketBeat
Bank of New York Mellon Corp Makes New $315,000 Investment in Q32 Bio Inc. (NASDAQ:QTTB) - MarketBeat
Bruce K. Posey Sells 1,330 Shares of Qualys, Inc. (NASDAQ:QLYS) Stock - Defense World
QXO (NASDAQ:QXO) Trading Up 4.7% - MarketBeat
Q32 Bio (NASDAQ:QTTB) Trading Down 3.7% - Defense World
Q32 Bio (NASDAQ:QTTB) Shares Down 3.7% - MarketBeat
Stock Surge: Qualigen Therapeutics Inc (QLGN) Closes at 0.17, Marking a -4.84 Increase/Decrease - The Dwinnex
Q32 Bio Inc.(NasdaqGM: QTTB) added to S&P Global BMI Index - Marketscreener.com
Mutual of America Capital Management LLC Trims Stock Position in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Client First Investment Management LLC Purchases New Stake in ProShares Ultra QQQ (NYSEARCA:QLD) - Defense World
Davidson Capital Management Inc. Boosts Holdings in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Inspire Investing LLC Acquires 2,595 Shares of Qualys, Inc. (NASDAQ:QLYS) - Defense World
Choreo LLC Makes New $264,000 Investment in Qualys, Inc. (NASDAQ:QLYS) - Defense World
Q32 Bio (NASDAQ:QTTB) Sees Strong Trading Volume - MarketBeat
Q32 Bio (NASDAQ:QTTB) Trading 8.2% Higher - MarketBeat
Harvard Management Co. Inc. Purchases New Stake in Q32 Bio Inc. (NASDAQ:QTTB) - MarketBeat
Q32 Bio Inc. (NASDAQ:QTTB) Receives $68.80 Average PT from Analysts - Defense World
EchoStar (NASDAQ:SATS) Hits New 12-Month High Following Analyst Upgrade - Defense World
Q32 Bio (NASDAQ:QTTB) Sets New 52-Week High at $52.64 - MarketBeat
Wells Fargo & Company Begins Coverage on Q32 Bio (NASDAQ:QTTB) - MarketBeat
Q 32 Bio Inc Stock (QTTB) Financials Data
There is no financial data for Q 32 Bio Inc (QTTB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Q 32 Bio Inc Stock (QTTB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Oct 11 '24 |
Option Exercise |
3.12 |
4,574 |
14,271 |
17,874 |
| Violette Shelia M. | Chief Scientific Officer |
Oct 08 '24 |
Option Exercise |
3.12 |
13,300 |
41,496 |
13,300 |
| TZIANABOS ARTHUR | Director |
Mar 25 '24 |
Sale |
24.20 |
265 |
6,413 |
7,983 |
| Alloway Paul | See Remarks |
Mar 25 '24 |
Sale |
24.21 |
268 |
6,488 |
2,596 |
| Michaud Charles Jr | See Remarks |
Mar 25 '24 |
Sale |
24.20 |
75 |
1,815 |
927 |
| TZIANABOS ARTHUR | Director |
Jan 09 '24 |
Sale |
0.57 |
13,037 |
7,445 |
128,778 |
| Alloway Paul | See Remarks |
Jan 03 '24 |
Sale |
0.57 |
7,280 |
4,120 |
28,036 |
| Michaud Charles Jr | See Remarks |
Jan 03 '24 |
Sale |
0.57 |
1,708 |
975 |
11,598 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):